- Home
- ACIC vs PGEN Comparison
ACIC vs PGEN Comparison
Compare ACIC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- PGEN
- Stock Information
- Founded
- ACIC 1999
- PGEN 1998
- Country
- ACIC United States
- PGEN United States
- Employees
- ACIC N/A
- PGEN N/A
- Industry
- ACIC Property-Casualty Insurers
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- PGEN Health Care
- Exchange
- ACIC Nasdaq
- PGEN Nasdaq
- Market Cap
- ACIC 556.0M
- PGEN 454.6M
- IPO Year
- ACIC N/A
- PGEN N/A
- Fundamental
- Price
- ACIC $11.16
- PGEN $1.33
- Analyst Decision
- ACIC Buy
- PGEN Strong Buy
- Analyst Count
- ACIC 1
- PGEN 4
- Target Price
- ACIC $16.00
- PGEN $7.33
- AVG Volume (30 Days)
- ACIC 149.9K
- PGEN 1.2M
- Earning Date
- ACIC 05-08-2025
- PGEN 05-20-2025
- Dividend Yield
- ACIC 4.48%
- PGEN N/A
- EPS Growth
- ACIC 3.34
- PGEN N/A
- EPS
- ACIC 1.49
- PGEN N/A
- Revenue
- ACIC $302,261,000.00
- PGEN $3,925,000.00
- Revenue This Year
- ACIC $6.68
- PGEN $189.12
- Revenue Next Year
- ACIC $7.93
- PGEN $1,093.07
- P/E Ratio
- ACIC $7.59
- PGEN N/A
- Revenue Growth
- ACIC 13.60
- PGEN N/A
- 52 Week Low
- ACIC $8.82
- PGEN $0.65
- 52 Week High
- ACIC $15.08
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- ACIC 44.64
- PGEN 39.77
- Support Level
- ACIC $11.19
- PGEN $1.23
- Resistance Level
- ACIC $11.97
- PGEN $1.66
- Average True Range (ATR)
- ACIC 0.36
- PGEN 0.11
- MACD
- ACIC 0.05
- PGEN -0.01
- Stochastic Oscillator
- ACIC 43.36
- PGEN 23.26
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.